Somatropin (HGH) vs Tesamorelin
A side-by-side research comparison of Somatropin (HGH) and Tesamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Somatropin (HGH) | Tesamorelin |
|---|---|---|
| Full name | Recombinant Human Growth Hormone | Tesamorelin Acetate (Egrifta) |
| Category | Growth Hormone | Growth Hormone |
| Status | Prescription medication | FDA Approved |
| Mechanism | Binds to GH receptors on target cells, triggering the JAK2/STAT5 signaling pathway. Stimulates hepatic IGF-1 production, promotes protein synthesis, mobilizes fatty acids from adipose tissue, and increases glucose output. | Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis. |
| Molecular weight | 22,124 Da | 5,136 Da |
| Half-life | 2-3 hours (subcutaneous); tissue effects persist 9-17 hours via IGF-1 | 26-38 minutes |
| Bioavailability | ~80% subcutaneous | High (SubQ) |
| Typical dose | 1-4 IU/day (anti-aging/wellness); 4-8 IU/day (performance) | 2 mg |
| Frequency | Daily (split AM/PM for higher doses) | Once daily |
| Route | Subcutaneous injection | Subcutaneous injection |
Somatropin (HGH) reported benefits
- Fat loss (especially visceral)
- Increased lean muscle mass
- Improved sleep quality
- Faster recovery from injury
- Improved skin elasticity
- Increased bone density
- Enhanced cognitive function
Tesamorelin reported benefits
- Visceral fat reduction (up to 18%)
- FDA-approved safety
- Improved lipid panels
- Cognitive benefits (emerging)
- No significant IGF-1 overshoot
Related comparisons
Research and educational reference only. Not medical advice.